Nuveen Asset Management LLC Has $47.64 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Nuveen Asset Management LLC reduced its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 304,115 shares of the company's stock after selling 7,740 shares during the period. Nuveen Asset Management LLC owned about 1.06% of Krystal Biotech worth $47,643,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Covestor Ltd raised its stake in Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after buying an additional 642 shares during the last quarter. Avanza Fonder AB acquired a new position in shares of Krystal Biotech during the fourth quarter worth approximately $119,000. KBC Group NV raised its position in Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after buying an additional 297 shares during the last quarter. Blue Trust Inc. raised its position in Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after buying an additional 433 shares during the last quarter. Finally, US Bancorp DE raised its position in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KRYS. HC Wainwright reaffirmed a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 6th. Jefferies Financial Group started coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital reiterated a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a research report on Wednesday, May 7th. Finally, Guggenheim dropped their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $211.13.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $132.29 on Tuesday. Krystal Biotech, Inc. has a one year low of $127.40 and a one year high of $219.34. The stock has a market capitalization of $3.82 billion, a P/E ratio of 44.24 and a beta of 0.79. The business's 50 day simple moving average is $165.82 and its two-hundred day simple moving average is $168.23.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.